Switch theme
Sign up to access all valuation multiples
Star Lake Bioscience Co Inc is a China-based Pharmaceutical manufacturer. The company is mainly engaged in the research, development, production, and sales of chemical raw materials and pharmaceutical intermediates. Products offered by the company include proline, guanosine, adenosine, adenine, adefovir dipivoxil, memantine hydrochloride, Proline, threonine, lysine, among others. Its products are used in food processing, feed processing, and pharmaceutical manufacturing. Star Lake sells its products through direct sales and distributors in China and overseas markets.
1992
2.7K+
LTM Revenue $2.5B
LTM EBITDA $337M
$1.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Star Lake Bioscience has a last 12-month revenue (LTM) of $2.5B and a last 12-month EBITDA of $337M.
In the most recent fiscal year, Star Lake Bioscience achieved revenue of $2.4B and an EBITDA of $305M.
Star Lake Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Star Lake Bioscience valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.5B | XXX | $2.4B | XXX | XXX | XXX |
| Gross Profit | $434M | XXX | $416M | XXX | XXX | XXX |
| Gross Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| EBITDA | $337M | XXX | $305M | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 13% | XXX | XXX | XXX |
| EBIT | $211M | XXX | $228M | XXX | XXX | XXX |
| EBIT Margin | 8% | XXX | 9% | XXX | XXX | XXX |
| Net Profit | $163M | XXX | $132M | XXX | XXX | XXX |
| Net Margin | 7% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $135M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Star Lake Bioscience's stock price is CNY 8 (or $1).
Star Lake Bioscience has current market cap of CNY 12.6B (or $1.8B), and EV of CNY 13.5B (or $1.9B).
See Star Lake Bioscience trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.9B | $1.8B | XXX | XXX | XXX | XXX | $0.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Star Lake Bioscience has market cap of $1.8B and EV of $1.9B.
Star Lake Bioscience's trades at 0.8x EV/Revenue multiple, and 6.2x EV/EBITDA.
Equity research analysts estimate Star Lake Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Star Lake Bioscience has a P/E ratio of 10.8x.
See valuation multiples for Star Lake Bioscience and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.8B | XXX | $1.8B | XXX | XXX | XXX |
| EV (current) | $1.9B | XXX | $1.9B | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | 5.6x | XXX | 6.2x | XXX | XXX | XXX |
| EV/EBIT | 9.0x | XXX | 8.3x | XXX | XXX | XXX |
| EV/Gross Profit | 4.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 10.8x | XXX | 13.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 7.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialStar Lake Bioscience's last 12 month revenue growth is 9%
Star Lake Bioscience's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.1M for the same period.
Star Lake Bioscience's rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Star Lake Bioscience's rule of X is 35% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Star Lake Bioscience and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | 18% | XXX | XXX | XXX |
| Rule of 40 | 19% | XXX | 21% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 35% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Star Lake Bioscience acquired XXX companies to date.
Last acquisition by Star Lake Bioscience was XXXXXXXX, XXXXX XXXXX XXXXXX . Star Lake Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Star Lake Bioscience founded? | Star Lake Bioscience was founded in 1992. |
| Where is Star Lake Bioscience headquartered? | Star Lake Bioscience is headquartered in China. |
| How many employees does Star Lake Bioscience have? | As of today, Star Lake Bioscience has 2.7K+ employees. |
| Is Star Lake Bioscience publicy listed? | Yes, Star Lake Bioscience is a public company listed on SHG. |
| What is the stock symbol of Star Lake Bioscience? | Star Lake Bioscience trades under 600866 ticker. |
| When did Star Lake Bioscience go public? | Star Lake Bioscience went public in 1994. |
| Who are competitors of Star Lake Bioscience? | Similar companies to Star Lake Bioscience include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Star Lake Bioscience? | Star Lake Bioscience's current market cap is $1.8B |
| What is the current revenue of Star Lake Bioscience? | Star Lake Bioscience's last 12 months revenue is $2.5B. |
| What is the current revenue growth of Star Lake Bioscience? | Star Lake Bioscience revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Star Lake Bioscience? | Current revenue multiple of Star Lake Bioscience is 0.8x. |
| Is Star Lake Bioscience profitable? | Yes, Star Lake Bioscience is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Star Lake Bioscience? | Star Lake Bioscience's last 12 months EBITDA is $337M. |
| What is Star Lake Bioscience's EBITDA margin? | Star Lake Bioscience's last 12 months EBITDA margin is 14%. |
| What is the current EV/EBITDA multiple of Star Lake Bioscience? | Current EBITDA multiple of Star Lake Bioscience is 5.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
